EUVIMEDEUVIMED entdecken
Crossref

Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System

Hannah Godfrey iD, Patrick Jedlowski, Rebecca Thiede

Australasian Journal of Dermatology · 2024

DOI: 10.1111/ajd.14262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von Hannah Godfrey und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration, Stevens-Johnson Syndrome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives The immune checkpoint inhibitors (ICIs) have been increasingly associated with severe cutaneous adverse reactions (SCARs). These reactions, including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are uncommon but potentially lethal. Despite the severity of these reactions and growing association with the ICIs, their specific risk and mortality rates have been largely unexplored.

Methods

A case/non‐case analysis was performed using data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to examine the reporting odds ratios (RORs) for ICI‐associated SCARs cases under two conditions: (1) ICIs compared with all drugs in FAERS and (2) ICIs compared with a reference group of pooled anticancer drugs to control for underlying malignancy.

Results

A statistically significant ROR for SJS (ROR: 5.44), TEN (ROR: 5.81) and DRESS (ROR: 1.38) were identified under Condition 1. Under Condition 2, this significance was maintained for SJS (ROR: 7.31), TEN (ROR: 7.40) and DRESS (ROR: 3.90), and mild significance was identified for AGEP (ROR: 1.89). Mortality rates for the ICIs were increased compared with the anticancer medications (28.5% vs. 24.5% for SJS, 55.3% vs. 46% for TEN, 3.0% vs. 2.1% for AGEP and 7.1% vs. 6.1% for DRESS).

Conclusions

Our results suggest an association between SCARs and the ICIs independent of cancer status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationStevens-Johnson SyndromeHumansUnited StatesDrug EruptionsFemaleMaleDrug Hypersensitivity SyndromeMiddle AgedAcute Generalized Exanthematous PustulosisAged

Stichwörter der Autor:innen

Stevens–Johnson syndromeacute generalized exanthematous pustulosisdrug reaction with eosinophilia and systemic symptomsimmune checkpoint inhibitorstoxic epidermal necrolysis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
  • Division of Dermatology, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.

ORCID-Profile: Hannah Godfrey

Zitieren

APA

Godfrey, H., Jedlowski, P., & Thiede, R. (2024). Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14262

Vancouver

Godfrey H, Jedlowski P, Thiede R. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System. Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14262

BibTeX
@article{Godfrey2024,
  author = {Godfrey, Hannah and Jedlowski, Patrick and Thiede, Rebecca},
  title = {Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non‐case analysis using the Food and Drug Administration Adverse Event Reporting System},
  journal = {Australasian Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ajd.14262}
}
Kostenlos starten →